Did you know you have an alarm system in the body that signals inflammation and can now be measured?
Enter galectin-3.
Galectin-3 is not from Star Trek but rather is a protein produced by many different cells of the body. Think of it as the pilot light for inflammation. When we are exposed to stress, infection, injuries – something the body needs to defend against – galactin-3 goes up.
Galectin-3 is a biomarker (think a window into the future) for heart disease, neurodegenerative diseases (Alzheimer’s and Parkinsons) and certain cancers. Galactin-3 drives aging and inflammaging. Most every chronic and acute disease is affected by galectin-3.
Some of the conditions linked to a high galectin-3 level are autoimmune disorders, cardiovascular disease, cancer, chronic kidney disease, chronic infections, diabetes, and liver cirrhosis.
The good news is it’s only $30 to check and most labs have the capacity to do it. Optimal levels are less than 11.0.
The other good news is there is an antidote to lowering galectin -3 and it is called modified citrus pectin.
Modified citrus pectin (MCP) is a fiber that comes from the peels of citrus fruits like oranges, lemons and limes. Issac Eliaz, MD, a respected physician who collaborates with National Institutes of Health and Harvard on research discovered how MCP can block galectin-3. It binds to galectin-3 and basically disarms it thus stopping it from creating damage to the body. It removes toxins and heavy metals, enhances the immune system and even can dissolve atherosclerotic plaque. There are over 80 published studies on how MCP helps multiple conditions.
MCP is a powder that can be mixed in water or sprinkled on food and can be taken -1-3 times per day. Since it is a prebiotic and made from fruit peels it is extremely safe and well tolerated. This is one supplement that should be in your arsenal to prevent and stop disease of all types. It’s easy, safe and a great game-changer for prevention of disease and maintenance of health.
Modified Citrus Pectin Research
2023 Clinical Study: Final Long-term Results of MCP Treatment in Biochemically Relapsed Prostate Cancer
2021 Clinical Study: Modified Citrus Pectin Reduces PSA and Disease Progression in Biochemically Relapsed Prostate Cancer
2021 Preclinical Study: Modified Citrus Pectin blocks Galectin-3 and alleviates cardiac hypertrophy and cardiac dysfunction
2021 Preclinical Study: Modified Citrus Pectin inhibits breast cancer development in mice
2021 Translational Study: Galectin-3 as an early biomarker and potential therapeutic target for post-cardiac kidney injury—Modified Citrus Pectin attenuates damage
2021 Translational Study: Galectin-3 involved in sepsis-induced kidney injury—Modified Citrus Pectin reduces damage
2021 Preclinical Study: Modified Citrus Pectin inhibits fat accumulation in Non-Alcoholic Fatty Liver
2020 Preclinical Study: Modified Citrus Pectin inhibits Galectin-3 to Reduce Diabetes-Associated Cognitive Impairment, Oxidative Stress and Neuroinflammation
2020 Preclinical Study: Modified Citrus Pectin Targets Hypoxia-Induced Galectin-3 in Breast Cancer
2019 Clinical Study Updated Results: Modified Citrus Pectin Halts Biochemically-Relapsed Prostate Cancer
2019 Review: The Pleiotropic Effects of Modified Citrus Pectin
2019 Preclinical Study: Modified Citrus Pectin Targets Galectin-3-Induced STAT3 Activation to Synergize with Chemotherapy Drug Paclitaxel Against Ovarian Cancer
2019 Preclinical Study: Modified Citrus Pectin Improves Ischemic Heart Failure by Downregulating Galectin 3 and Reducing Myocardial Fibrosis
2019 Preclinical Study: Modified Citrus Pectin Blocks Galectin-3 to Prevent Profibrotic and Proinflammatory Effects of Cardiotrophin-1 (CT-1) in Myocardial Fibrosis
2019 Preclinical Study: Modified Citrus Pectin Blocks Galectin-3 and Prevents Cardiac Damage, Inflammation, and Fibrosis Following Kidney Injury
2019 Preclinical Study: Modified Citrus Pectin Blocked Galectin-3 and Reduced the Pro-Inflammatory, Pro-fibrotic, and Pro-osteogenic Response in Aortic valves in Patients Undergoing Aortic Valve Replacement
2019 Preclinical Study: Modified Citrus Pectin Blockade of Galectin-3 Prevents Cardiac Fibrosis, Inflammation and Functional Alterations
2019 Clinical Case Study: Modified Citrus Pectin and Alginate Combo Safely Remove Uranium
2018 Preclinical Study: Modified Citrus Pectin Prevents Blood-Brain Barrier Disruption in Mouse Subarachnoid Hemorrhage by Inhibiting Galectin-3
2018 Preclinical Study: Modified Citrus Pectin Blocks Galectin-3 and Protects Against Renal Injury and Fibrosis
2018 Clinical Study (Interim Results): Modified Citrus Pectin Halts Biochemically Relapsed Prostate Cancer
2018 Preclinical Study: Modified Citrus Pectin Inhibits Colon Cancer Migration via Galectin-3 Inhibition
2018 Practice Survey: Modified Citrus Pectin at Top of List for Naturopathic Treatment of Thoracic Cancer
2018 Preclinical Study: Modified Citrus Pectin Enhances Radiotherapy Against Prostate Cancer
2018 Preclinical Study: Modified Citrus Pectin Increases Antioxidant Activity and Reduces Oxidative Stress in Hypertension Model, through Inhibition of Galectin-3
2018 Preclinical Study: Modified Citrus Pectin Inhibits Bladder Tumor Growth through Downregulation of Galectin-3
2018 Preclinical Study: Inhibition of Galectin-3 with Modified Citrus Pectin Mitigates Diet-Induced Cardiac Lipotoxicity and Reduces Mitochondrial Damage
2018 Preclinical Study: Inhibition of Galectin-3 with Modified Citrus Pectin Reduces Inflammatory Mediators and Decreases Kidney Damage in Spontaneous Hypertension Model
2017 Preclinical Study: Modified Citrus Pectin Protects Vascular Tissue against Abdominal Aortic Aneurism by Decreasing Galectin-3 and Inflammatory Cytokine Expression
2017 Preclinical Study: Modified Citrus Pectin Combined with Alginate and Live Probiotic, Lactobacillus acidophilus Offered Benefit to Improve the Intestinal Lactobacilli Microbiota in Healthy Host
2017 Observational Study: Modified Citrus Pectin Listed Among Researched Nutrients with Anti-Carcinogenic Properties to Reduce CTC Count
2017 Preclinical Study: Modified Citrus Pectin Protects Against Shiga Toxin Adhesion and Cytotoxicity, via Prebiotic Actions
2017 Preclinical Study: Modified Citrus Pectin Reduces Size of Atherosclerotic Lesions, via Inhibition of Galectin-3
2017 Preclinical Study: Modified Citrus Pectin Blocks Galectin-3 to Prevent Cardiac Remodeling, Fibrosis and Inflammation Associated with Early Aortic Stenosis
2017 Preclinical Study: Modified Citrus Pectin and Pure Honokiol Offer Synergistic Antioxidant and Anti-inflammatory Effects, Reduce Tumor Necrosis-α (TNF-α), Nuclear factor-kappa B, Cyclooxygenase-II, and Lipid Peroxidation
2017 Preclinical Study: Modified Citrus Pectin Gives Additive Antibacterial Effect in Combination with Cefotaxime Against Staphylococcus aureusInfection
2017 Preclinical Study: Galectin-3 inhibition with Modified Citrus Pectin Blocks Inflammation, Fibrosis and Calcification in Aortic Valves
2016 Preclinical Study: Modified Citrus Pectin Reduces Renal Fibrosis, Inflammation and Damage, Through Inhibition of Galectin-3
2016 Preclinical Study: Modified Citrus Pectin Blocks Inflammation and Fibrosis and Prevents Calcification in Aortic Stenosis, via Inhibition of Galectin-3
2016 Preclinical Study: Modified Citrus Pectin Prevents Adipose (Fat)Tissue Remodeling in Obesity, via Inhibition of Galectin-3
2016 Preclinical Study: Modified Citrus Pectin Stops Progression of Liver Fibrosis Through Antioxidant Effect, Galectin-3 Inhibitionand Induction of Apoptosis
2016 Preclinical Study: Modified Citrus Pectin Inhibits Growth and Metastasis of Gastrointestinal Cancer Cells
2016 Preclinical Study: Modified Citrus Pectin Prevents Left Ventricle Dysfunction and Cardiac Fibrosis, through Inhibition of Galectin-3
2016 Preclinical Study: Modified Citrus pectin Suppresses Neuropathic Pain and Decreases Proinflammatory Mediators Following Peripheral Nerve Injury, via Inhibition of Galectin-3
2015 Preclinical Study: Modified Citrus Pectin Prevents Obesity-Related Cardiovascular Remodeling, through Inhibition of Galectin-3
2015 Preclinical Study: Modified Citrus Pectin Blocks Galectin-3 to Inhibit Cardiac Inflammation and Fibrosis in Experimental Hypertension
2015 Preclinical Study: Modified Citrus Pectin and Alginate Probiotic Combination offer Chemopreventive Effect against Colon Cancer Cells
2015 Preclinical Study: Modified Citrus Pectin Prevents Cardiac and Kidney Fibrosis, via Inhibition of Galectin-3
2013 Preclinical Study: Modified Citrus Pectin Reverses Vascular Hypertrophy and Fibrosis, via Inhibition of Galectin-3
2013 Preclinical Study: Modified Citrus Pectin Traverses Small Intestinal Epithelium Demonstrating increased Bioavailability
2013 Preclinical Study: Modified Citrus Pectin Demonstrates Synergistic Effect with Polybotanical Compounds for Breast and Prostate Cancer
2012 Preclinical Study: Synergistic Effects of Modified Citrus Pectin and Doxorubicin against Prostate Cancer Cells
2011 Preclinical Study: Modified Citrus Pectin Reduces Kidney Disease Severity by Reducing Galectin-3 Expression
2011 Preclinical Study: Modified Citrus Pectin Activates Powerful Immune Response
2011 Preclinical Study: Activation and Induction of Natural Killer Cell Activity Against Leukemia Cells with Modified Citrus Pectin
2010 Preclinical Study: Modified Citrus Pectin Inhibits Prostate Cancer
2010 Review: Modified Citrus Pectin Anti-Metastatic Properties
2009 Preclinical Study: Modified Citrus Pectin Binds to Galectin-3
2008 Clinical Study: The Role of Modified Citrus Pectin as an Effective Chelator of Lead in Children Hospitalized with Toxic Lead Levels
2007 Clinical Study: The Role of Modified Citrus Pectin/Alginates in Heavy Metal Chelation and Detoxification
2007 Clinical Study: Modified Citrus Pectin Clinical Benefit in Patients with Advanced Solid Tumors
2006 Clinical Study: The Effect of Modified Citrus Pectin on the Urinary Excretion of Toxic Elements
2003 Clinical Study: Modified Citrus Pectin (MCP) Increases the Prostate-Specific Antigen Doubling Time in Men with Prostate Cancer: A Phase II Pilot Study
